| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Interspinous and Interlaminar Stabilization/Distraction Devices (Spacers) | 2025-11-03 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Omalizumab (Xolair) and Omalizumab Biosimilars | 2025-11-03 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Trastuzumab (Herceptin), Trastuzumab Biosimilars, and Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) | 2025-11-03 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Zoledronic Acid (Reclast, Zometa) | 2025-11-03 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Treatment of Hereditary Angioedema (HAE) | 2025-11-03 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Zopapogene Imadenovec-drba (Papzimeos) | 2025-11-03 |
| BCBS Highmark Penn Medicare Advantage | Programmed Death Receptor (PD-1)/ Programmed Death-Ligand (PD-L1) Blocking Antibodies | 2025-11-03 |
| BCBS Highmark Penn Medicare Advantage | Trastuzumab (Herceptin), Trastuzumab Biosimilars, and Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) | 2025-11-03 |
| BCBS Highmark Penn Medicare Advantage | Zopapogene Imadenovec-drba (Papzimeos) | 2025-11-03 |
| BCBS Highmark Penn Medicare Advantage | Treatment of Hereditary Angioedema (HAE) | 2025-11-03 |